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Epstein-Barr Virus (EBV) latent membrane protein 1 (LMP1) is required for EBV B-lymphocyte transfor-
mation, transforms rodent fibroblasts, and can induce lymphoma and epithelial hyperplasia in transgenic
mice. Two domains have been identified within the intracellular carboxy terminus that can activate NF-B,
C-terminus-activating region 1 (CTAR1) and CTAR2, through interactions with tumor necrosis receptor-
associated factors (TRAFs). CTAR1 can activate both the canonical and noncanonical NF-B pathways and
has unique effects on cellular gene expression. The epidermal growth factor receptor (EGFR) is highly induced
by LMP1-CTAR1 in epithelial cells through activation of a novel NF-B form containing p50 homodimers and
Bcl-3. To further understand the regulation of NF-B in CTAR1-induced EGFR expression, we evaluated the
ability of CTAR1 to induce EGFR in mouse embryonic fibroblasts (MEFs) defective for different NF-B
effectors. CTAR1-mediated EGFR induction required the NF-B-inducing kinase (NIK) but not the IB kinase
(IKK) complex components that regulate canonical or noncanonical NF-B pathways. CTAR1-mediated
induction of nuclear p50 occurred in IKK-, IKK-, and NIK-defective MEFs, indicating that this induction
is not dependent on the canonical or noncanonical NF-B pathways. EGFR and nuclear p50 were expressed
at high levels in TRAF2/ fibroblasts and were not induced by CTAR1. In TRAF3/ MEFs, CTAR1 induced
nuclear p50 but did not affect basal levels of STAT3 serine phosphorylation or induce EGFR expression. EGFR
was induced by LMP1 in TRAF6/ MEFs. These findings suggest that this novel NF-B pathway is differ-
entially regulated by TRAF2 and TRAF3, and that distinct interactions of LMP1 and its effectors regulate
LMP1-mediated gene expression.
Epstein-Barr virus (EBV) is a human gammaherpesvirus
that infects more than 95% of the world population and is
associated with multiple malignancies, including Hodgkin’s
disease (HD), NK or T-cell lymphoma, Burkitt’s lymphoma
(BL), posttransplant lymphoproliferative disease (PTLD), gas-
tric carcinoma (GAC), and nasopharyngeal carcinoma (NPC)
(43). Latent membrane protein 1 (LMP1) is considered the
EBV oncogene and is essential for EBV-mediated B-cell trans-
formation (20). Moreover, LMP1 can transform rodent fibro-
blast cells, and LMP1-transgenic mice develop B-cell lym-
phoma and epithelial hyperplasia (23, 32, 55, 56). LMP1 is
expressed in multiple EBV-associated malignancies and acts as
a constitutively active tumor necrosis factor receptor (TNFR)
by recruiting TNFR-associated factors (TRAFs) to the cell
membrane (21, 50). Numerous cellular genes have been shown
to be induced by LMP1, including ICAM-1, TRAF1, A20, Id1,
Id3, Bcl-2, Bcl-3, and epidermal growth factor receptor (EGFR)
(24, 25, 36, 45, 49). LMP1 has two major signaling domains,
C-terminus-activating region 1 (CTAR1) and CTAR2, which
bind different TRAFs and activate distinct signaling pathways.
CTAR1 recruits TRAF1, -2, -3, and -5 and uniquely activates
noncanonical nuclear factor B (NF-B), phosphatidylino-
sitol 3-kinase (PI3K)-Akt, and the mitogen-activated pro-
tein kinase (MAPK) pathways. CTAR2 recruits TRAF2 and
TRAF6 through adaptors TRADD and BS69 to activate
canonical NF-B and c-Jun N-terminal kinase (JNK) signal-
ing pathways (8, 18, 32, 33, 42). CTAR1 is required for
LMP1-mediated fibroblast transformation and for B-lym-
phocyte transformation while CTAR2 is dispensable (32, 33).
NF-B is a transcription factor family whose members
dimerize and bind to B sites within the promoter/enhancers
to regulate transcription of genes that affect a variety of bio-
logical processes, including cell cycle progression, apoptosis,
differentiation, inflammation, angiogenesis, and cell prolifera-
tion (15, 34). The NF-B family consists of five members, p50,
p52, p65 (RelA), RelB, and c-Rel, all of which share a Rel
homology domain responsible for dimerization and DNA bind-
ing. The transcription activation domain required for gene
regulation is found in p65, RelB, and c-Rel. The activation of
NF-B is tightly regulated through interactions with inhibitors
of NF-B (IBs), which include p105 (precursor of p50), p100
(precursor of p52), IB, IB, IB, IBε, IB, and Bcl-3.
IBs function mainly by sequestering inactive NF-B dimers in
the cytoplasm to prevent their activity. Upon receiving an ex-
tracellular stimulus, such as binding of tumor necrosis factor
alpha (TNF-) to its receptor, activation of a kinase cascade
that includes IB kinase alpha (IKK), IKK, and IKK
(NEMO) results in the phosphorylation of IBs and leads to
their ubiquitination and degradation. NF-B members are
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then released into the nucleus for transcriptional regulation. In
the canonical NF-B pathway, an IKK complex consisting of
IKK, IKK, and IKK is activated and results in IKK/IKK-
mediated phosphorylation and degradation of IB. Degrada-
tion of IB releases multiple NF-B dimers, primarily p50/
p65, into the nucleus. In the noncanonical NF-B pathway,
NF-B-inducing kinase (NIK) phosphorylates and activates
IKK in an IKK/-independent manner. Activated IKK
phosphorylates p100 and triggers proteasome-mediated pro-
cessing of p100 to p52, liberating p52-containing NF-B dimers
such as p52/RelB into the nucleus. Due to the very different
mechanisms of activation, canonical and noncanonical NF-B
pathways likely regulate distinctive target genes. In addition to
participating in both NF-B pathways, IKKs and NIK have
also been reported to phosphorylate many other proteins be-
sides the IBs. For example, IKK and IKK can both directly
phosphorylate p65 (41). IKK has also been implicated in
the phosphorylation of several nuclear substrates, including
SMRT, histone H3, and CBP (16, 17, 58). NIK was recently
suggested to function as a serine kinase of STAT3 (39). The
aberrant regulation of NF-B activation pathways has been
implicated in development of many human cancers (34, 44).
Initial studies characterizing LMP1 activation of NF-B
showed that although CTAR2 induced greater NF-B activa-
tion as determined using reporter assays, CTAR1 induced
more complex NF-B signaling detected by electrophoretic
mobility shift assay (EMSA) (19, 35, 52). Subsequent studies
revealed that CTAR2 only activates the canonical NF-B path-
way, whereas CTAR1 can activate both the canonical and
noncanonical pathways (1, 9, 30, 46). LMP1-CTAR1 can tran-
scriptionally activate EGFR expression, and this ability was
shown to be mediated through a unique NF-B complex con-
taining p50 homodimers and Bcl-3 (24, 36, 53). The induction
of this transcription complex requires activation of STAT3 by
CTAR1 to increase Bcl-3 expression. Although it is considered
a member of the IB family, Bcl-3 contains a transactivating
domain and can bind to p50 and p52 homodimers to induce
their transcriptional activating potential (4, 13).
To determine if NF-B-regulated EGFR expression re-
flected the activation of the canonical or noncanonical NF-B
pathway, the effects of LMP1-CTAR1 were analyzed in genet-
ically engineered mouse embryonic fibroblasts (MEFs). LMP1-
CTAR1-mediated upregulation of EGFR was independent of
canonical or noncanonical regulation, as it did not require
IKK, IKK, or IKK, but was dependent on NIK. In addi-
tion, TRAF2 and TRAF3, but not TRAF6, were required for
LMP1-CTAR1-mediated induction of EGFR in MEF cells.
These data indicate that in addition to canonical and non-
canonical NF-B pathways, LMP1 also induces unique NF-B
complexes through CTAR1 to regulate target gene expres-
sions.
MATERIALS AND METHODS
Reagents and cell culture. C33A cervical carcinoma cells were cultured in
Dulbecco’s modified Eagle’s medium (Gibco) supplemented with 10% fetal
bovine serum (Sigma) and antibiotic/antimycotic (Gibco) at 37°C with 5% CO2.
Wild-type (WT), IKK/, IKK/, IKK/, NIKaly/aly, TRAF2/, and
TRAF6/ mouse embryonic fibroblast (MEF) cells were kindly provided by
Elliot Kieff (Harvard University, Boston) and were immortalized by being in-
fected with a human papillomavirus 16 E6/E7 retrovirus to make MEF cells
susceptible for transfection or transduction (7, 26, 29–31, 47). TRAF3/ MEF
cells were obtained from Michael Karin (University of California at San Diego)
and were spontaneously immortalized by continuous passaging (14). Immortal-
ized MEF cells were maintained in Dulbecco’s modified Eagle’s medium (Gibco)
supplemented with 10% fetal bovine serum (Sigma) and antibiotic/antimycotic
(Gibco) at 37°C with 5% CO2. To inhibit proteasome activity, 1 to 10 M MG132
(26S inhibitor) or clasto-lactacystin -lactone (20S inhibitor) (Calbiochem) was
added to 90% confluent cells and left for 5 h before preparation of cell lysates.
Plasmids. Generation of plasmid constructs expressing both Myc-tagged
(pCDNA3) and hemagglutinin (HA)-tagged (pBabe) full-length LMP1, LMP1-
CTAR1 (which contains amino acids [aa] 1 to 231 of LMP1), and LMP1-CTAR2
(which has aa 187 to 351 of LMP1 deleted) was described previously (10).
Myc-tagged and HA-tagged LMP1 constructs contain neomycin and puromycin
resistance cassettes, respectively. HA-tagged LMP1, LMP1-CTAR1, and LMP1-
CTAR2 were also subcloned into pCDNA3 vector with a zeocin resistance
cassette by digesting pBabe-LMP1/CTAR1/CTAR2 with BamHI/EcoRI and
ligated to BamHI/EcoRI-digested pCDNA3.1-zeocin vector (Invitrogen). Wild-
type and dominant negative NIK constructs were kindly provided by Christian
Jobin (University of North Carolina at Chapel Hill) and Elliot Kieff (Harvard
University).
Retrovirus production and transduction. Recombinant retrovirus production
and transduction were performed as previously described to transduce full-length
LMP1, CTAR1(1–231), CTAR2(d187-351), or pBabe vector control (24). Briefly,
60 to 80% confluent 293T cells in 100-mm plates were triply transfected using
FuGEGE6 transfection reagent (Roche) according to the manufacturer’s instruction
with 5 g pBabe (vector), pBabe-HA-LMP1, pBabe-HA-CTAR1, or pBabe-HA-
CTAR2 and 5 g pVSV-G- and 5 g pGag/Pol-expressing plasmids. After 24 h of
incubation at 37°C, the culture media were replaced with fresh media and the
cells were transferred to 33°C for another 24 h of incubation. Cell superna-
tants were centrifuged at 1,000 	 g for 5 min to remove cell debris, and
virus-containing supernatant was collected and stored in 80°C if not imme-
diately used. Cells to be transduced were grown to 70 to 80% confluence
and then transduced with virus-containing supernatant with 4 g/ml Poly-
brene for 24 to 48 h at 37°C.
Generation of stable cell lines. C33A stable cell lines expressing CTAR1
(1–231) or vector control pBabe were established by retroviral transduction
followed by selection and passages in the presence of 1 g/ml puromycin
(Sigma). IKK/ and NIKaly/aly MEF cells stably expressing CTAR1 were
generated by transducing cells with pBabe- and CTAR1-containing retrovirus
solution with 4 g/ml Polybrene for 24 to 48 h at 37°C, followed by selection and
passages in the presence of 1 g/ml puromycin. IKK/ and IKK/ MEF
cells stably expressing CTAR1 were made by transfecting cells with Myc-tagged
pCDNA3 vector or pCDNA3-CTAR1 construct using FuGEGE6 transfection
reagent for 48 h at 37°C, followed by selection and passages in the presence of
0.8 mg/ml G418 (Mediatech). Stable LMP1- and CTAR1-expressing TRAF2/
and TRAF6/ MEF cells were generated by transfecting cells with HA-tagged
pCDNA3.1 vector, pCDNA3.1-LMP1, or pCDNA3.1-CTAR1 construct using
FuGEGE6 transfection reagent for 48 h at 37°C, followed by selection and
passages in the presence of 400 g/ml zeocin (Invitrogen).
Fractionation of cells. Cells were fractionated as previously described (24).
Briefly, after cultured cells reached 90% confluence, cells were scrape har-
vested, washed once with cold phosphate-buffered saline (PBS) (Gibco), and
centrifuged at 1,000 	 g for 5 to 10 min to get cell pellets. Whole-cell lysates were
made by lysing cells with radioimmunoprecipitation assay (RIPA) buffer (20 mM
Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% sodium
dodecyl sulfate [SDS], 0.1% deoxycholic acid) supplemented with phenylmethyl-
sulfonyl fluoride (PMSF), sodium orthovanadate (Na3VO4), and protease and
phosphatase inhibitor cocktails (Sigma). After incubation at 4°C for 15 min,
lysates were then clarified by centrifugation at 13,000 rpm and 4°C for 15 min,
and supernatants containing whole-cell lysates were transferred to new tubes.
Nuclear extracts were made by lysing initial cell pellets in a hypotonic buffer
(20 mM HEPES, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA) supplemented
with PMSF, Na3VO4, and protease and phosphatase inhibitor cocktails (Sigma)
for 15 min on ice. Nonidet P-40 was then added to a final concentration of 1%,
followed by 1 min of vortexing. Nuclei were pelleted by low-speed centrifugation
at 2,000 rpm for 10 min at 4°C, and the supernatant was collected as the
cytoplasmic fraction. The nuclear fraction was purified using the Optiprep re-
agent (Sigma) as directed by the manufacturer. Nuclei were lysed with nuclear
extraction buffer (20 mM Tris-HCl [pH 8.0], 420 mM NaCl, 1.5 mM MgCl2, 0.2
mM EDTA, 25% glycerol, PMSF, Na3VO4, and protease and phosphatase in-
hibitor cocktails [Sigma]) with the salt concentration adjusted to 400 mM with 5
M NaCl. All lysates were stored at 80°C.
Western blot analysis. The protein concentration in cell lysates was deter-
mined using Bio-Rad DC protein assay system according to the manufacturer’s
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instructions. Equal amounts of protein were used for SDS-polyacrylamide gel
electrophoresis (PAGE) and transferred to Optitran (Schleicher and Schuell) for
Western blot analysis. Primary antibodies used included anti-p50 (Abcam), anti-
p65 (RelA), anti-NIK, anti-RelB, anti-GAPDH (glyceraldehyde-3-phosphate de-
hydrogenase), anti-GRP78, anti-PARP [poly(ADP-ribose) polymerase] (Santa
Cruz), anti-emerin, anti-phospho-STAT3 (Ser 727 and Tyr 705) (Cell Signaling),
anti--catenin (BD Biosciences), and anti-HA tag (Covance). A rabbit antiserum
raised against the carboxyl-terminal 100 amino acids of the EGFR fused to
glutathione S-transferase was kindly provided by H. Shelton Earp (University of
North Carolina at Chapel Hill) and used to detect total EGFR expression. S12
monoclonal antibody against LMP1 was a kind gift of David A. Thorley-Lawson
(Tufts University). Secondary antibodies used to detect bound proteins include
horseradish peroxidase-conjugated anti-mouse and anti-rabbit (Amersham Phar-
macia) and anti-goat (Dako) antibodies. After treatment with secondary anti-
bodies, blots were developed using the Pierce SuperSignal West Pico chemilu-
minescence system followed by exposure to film (ISCBioexpress).
RESULTS
LMP1 effects on EGFR expression in mouse embryonic fi-
broblast cells. To assess the induction of EGFR expression by
LMP1 in mouse embryonic fibroblast (MEF) cells, full-length
LMP1, LMP1-CTAR1, and LMP1-CTAR2 were expressed us-
ing the pBabe retroviral vector and transduced into wild-type
MEF cells. The expression of LMP1, deletion mutants, and
EGFR was determined by immunoblotting (Fig. 1). A higher-
molecular-weight band was consistently detected in the CTAR1
deletion mutant, which may represent a nondenatured oligomer
of LMP1. EGFR was readily detected in the WT MEFs, and both
LMP1 and LMP1-CTAR1 increased EGFR expression, while
LMP1-CTAR2 alone did not affect it, similar to previous reports
(24, 53). The induction of EGFR by LMP1 was less in the MEF
cells than what was previously shown in the C33A cells, a differ-
ence that likely reflects the higher basal levels of EGFR expres-
sion in the MEFs.
CTAR1-mediated EGFR upregulation is NIK dependent,
but NIK is not sufficient to mimic LMP1-mediated EGFR
induction. CTAR1 of LMP1 activates both the canonical and
noncanonical NF-B pathways to activate distinct NF-B com-
plexes, including p50/65, p52/p50, p52/RelB, and p50/50 (35,
42). The activation of canonical or noncanonical NF-B is
linked to complexes that contain different members of the
inhibitor of NF-B kinase kinases (IKK). The canonical path-
way requires IKK, IKK, and in some instances IKK, while
the noncanonical pathway requires the activation of IKK
resulting from phosphorylation by the NF-B-inducing kinase,
NIK. The effects of expression of LMP1 or CTAR1 on EGFR
and serine and tyrosine phosphorylation of STAT3 were eval-
uated in MEF cells lacking these regulators of NF-B pathway
(Fig. 2). LMP1 or LMP1-CTAR1 induced EGFR protein in
IKK-, IKK-, and IKK-defective MEF cells. As these IKKs
are required for activation of the canonical NF-B pathway,
these data indicate that LMP1-mediated EGFR upregulation
is not dependent on the canonical NF-B pathway. Moreover,
since IKK is the critical regulator in the noncanonical NF-B
pathway, the result also reveals that the noncanonical NF-B
pathway is not required for LMP1-mediated EGFR induc-
tion. Interestingly, EGFR expression was not induced by
CTAR1 in NIKaly/aly MEF cells. These results suggest that
LMP1 induces EGFR through an IKK-independent but
NIK-specific pathway.
Activation of STAT3 by LMP1 is required for induction of
Bcl-3 and EGFR expression (24). Expression of LMP1 in-
creased serine phosphorylation of STAT3 in wild-type and
IKK- and IKK-defective MEF cells but not in IKK-defec-
tive or NIKaly/aly MEFs, both of which had high basal levels.
Elevated tyrosine phosphorylation was detected in wild-type,
IKK-defective and NIKaly/aly cells but not in IKK- or IKK-
defective MEF cells. Importantly, the effects of LMP1 on
EGFR and STAT3 were not linked to the canonical or non-
canonical NF-B pathways but were linked to the presence
of NIK.
A previous study showed that NIK could function as a serine
kinase of STAT3; however, the high basal levels of serine-
phosphorylated STAT3 in NIK-defective cells indicate that
other kinases may also phosphorylate STAT3 (39). To confirm
the requirement for NIK in LMP1-induced EGFR expression,
CTAR1-expressing C33A cells were transiently transfected
with a dominant negative NIK construct (DNNIK), DNNIK
with an aly mutation (G860R; NIK-aly), or kinase-dead NIK
[NIK(K-A)] for 48 h, and the expression levels of EGFR and
serine-phosphorylated STAT3 were analyzed by immunoblot-
ting (Fig. 3A). DNNIK and NIK-aly express the C terminus of
NIK, which contains the TRAF/IKK binding domain but not
the kinase domain. NIK-aly does not interact with IKK, and
previous studies have suggested that this residue is also re-
quired for inhibition of LMP1-mediated NF-B by DNNIK.
NIK(K-A) expresses the full-length NIK with two mutations at
Lys429 and Lys430 in the kinase domain (K429A/K430A),
which abrogates its kinase activity (31, 51). Using an antibody
to the carboxy terminus of NIK, expression of all three NIK
mutants was detected with high levels of the kinase-dead
NIK(K-A). Transfection of NIK(K-A), but not DNNIK or
FIG. 1. EBV LMP1-CTAR1 mediates mild induction of EGFR ex-
pression in mouse embryonic fibroblast (MEF) cells. Control vector
pBabe, full-length LMP1, truncated LMP1 containing only CTAR1, or
truncated LMP1 containing only CTAR2 was transduced into wild-type
MEF cells. Expression of EGFR and LMP1 derivatives was analyzed by
immunoblotting with EGFR and HA tag antibodies, respectively. Expres-
sion of GRP78 was measured by immunoblotting as a loading control.
Arrows indicate the sizes of different LMP1 deletion constructs. The
results shown here are representative of three independent experiments.
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NIK-aly, reduced CTAR1-induced EGFR expression signifi-
cantly, by 35%. NIK(K-A) also decreased CTAR1-induced
serine phosphorylation of STAT3 by 34%, while DNNIK and
NIK-aly did not have significant effects. These findings indicate
that NIK contributes to LMP1-mediated STAT3 serine phos-
phorylation and EGFR induction but not through its interac-
tion with IKK.
To determine whether NIK itself is sufficient to induce Ser-
pSTAT3 and EGFR upregulation, wild-type NIK was tran-
siently transfected into both C33A and 293T cells and EGFR
expression and Ser-pSTAT3 were assessed by Western blot
analysis (Fig. 3B). NIK expression was clearly detected in
C33A and 293T cells. However, overexpression of NIK did not
induce Ser-pSTAT3 or EGFR expression. In C33A cells, trans-
fection of 4 g of NIK very slightly increased Ser-pSTAT3, but
it failed to induce expression of EGFR.
It is possible that activation of additional pathways by CTAR1
in combination with NIK is required to induce STAT3 activation
and EGFR expression. Therefore, increasing amounts of the WT
NIK construct were transfected into CTAR1-expressing NIKaly/aly
MEF cells. Expression of CTAR1 was confirmed by Western blot
analysis using antibody to the HA tag, and the effects on EGFR
and Ser-pSTAT3 were determined (Fig. 3C). Similarly to the
results observed in 293T and C33A cells, overexpression of NIK
in NIKaly/aly MEF cells was not sufficient to induce either Ser-
pSTAT3 or EGFR expression, even in the presence of CTAR1.
These results suggest that although NIK is required for CTAR1-
mediated EGFR upregulation, NIK overexpression alone is not
sufficient to induce these pathways, and additional factors or pro-
cesses are required for Ser-pSTAT3 and EGFR induction.
CTAR1-mediated p50 activation is not dependent on the
canonical or noncanonical NF-B pathway. LMP1 induction
of EGFR transcription is mediated through effects on Bcl-3
and induction of p50 homodimers (24, 52, 53). To determine
the requirement for specific IKK complexes on CTAR1-medi-
ated p50 activation, CTAR1-expressing wild-type, IKK,
IKK, and NIKaly/aly MEF cells were fractionated, and the
nuclear lysates were analyzed to detect nuclear expression of
p65, p50, and RelB (Fig. 4). The expression of PARP was
analyzed as a loading control for the nuclear lysates. Nuclear
translocation of p65 is characteristic of the canonical pathway,
and p65 was detected in the nuclear lysates from WT, IKK,
and NIKaly/aly MEFs but not in those from IKK-defective
cells. Nuclear RelB is the major form of NF-B that represents
the noncanonical pathway, and CTAR1 induced nuclear trans-
location of RelB in wild-type and IKK-defective MEF cells
but not in NIK-defective cells. These findings confirm that
CTAR1-mediated translocation of p65 reflects activation of
the canonical pathway and that the effects of CTAR1 on RelB
require the noncanonical pathway. In contrast, the nuclear
expression of p50 was significantly induced by CTAR1 in
IKK, IKK, and NIKaly/aly MEF cells. This indicates that
CTAR1-mediated p50 activation and nuclear translocation are
distinct from its effects on either the canonical and noncanoni-
cal NF-B pathways. A high basal level of nuclear p50 was
detected in wild-type MEF cells and may be linked to the
higher level of EGFR in WT MEFs and the slight effects of
LMP1 on EGFR expression compared to that in C33A cells.
LMP1-mediated p50 activation is proteasome dependent.
The mechanisms responsible for p50 activation have not been
clearly defined. Several studies have indicated that p50 can be
activated by a proteasome-dependent mechanism that either
modulates p105 processing or impairs ribosomal progression
(22). To determine whether p50 is activated by CTAR1
through proteasome-mediated mechanisms, C33A cells stably
transduced with vector or CTAR1 were treated with dimethyl
sulfoxide (DMSO) or a proteasome inhibitor, MG132 (26S
inhibitor) or clasto-lactacystin -lactone (20S inhibitor) (Fig.
5). The effects of these inhibitors on p105/50 were assessed by
immunoblotting using anti-p105/50 antibody. -Catenin is a
known target of proteasomal degradation and was analyzed
as a positive control for inhibition of proteasome activity.
FIG. 2. LMP1-mediated EGFR upregulation is NIK dependent. Full-length LMP1 or CTAR1 was transduced or transfected into wild-type
MEF cells or MEF cells defective for IKK, IKK, IKK, or NIK. Expression of LMP1 or CTAR1 was confirmed by immunoblotting with specific
antibody against HA tag (wild-type, IKK/, and NIKaly/aly MEF cells) or Myc tag (IKK/ and IKK/ MEF cells). Expression levels of
EGFR, serine-phosphorylated STAT3, or tyrosine-phosphorylated STAT3 were analyzed by immunoblotting. Expression of GRP78 was measured
by immunoblotting as a loading control. V, vector control; L1, LMP1; C1, CTAR1. The data are representative of at least three independent
experiments.
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GAPDH and emerin were analyzed as loading controls for
whole-cell lysates and nuclear lysates, respectively. In CTAR1-
expressing C33A cells where nuclear expression of p50 was
significantly induced, treatment with 1 M or 10 M MG132
reduced the p50 translocation level by 72% and 64%, respec-
tively (Fig. 5A). Similarly, treatment with 1 M or 10 M
clasto-lactacystin -lactone reduced CTAR1-induced p50 nu-
clear translocation by 35% and 69%, respectively. Nuclear p50
was not detected in the C33A cells transduced with the pBabe
control plasmid, and treatment with proteasome inhibitors did
not have a significant effect (data not shown). This result
indicates that LMP1-CTAR1 induction of p50 nuclear trans-
location is mediated through effects on proteasome activity.
-Catenin expression was slightly higher in C33A cells ex-
pressing LMP1, which is consistent with the described ef-
fects of LMP1 on junctional proteins (48). In cells treated
with proteasome inhibitors, -catenin levels were increased
in control and CTAR1-expressing cells and higher-molecu-
lar-weight forms of -catenin were detected, reflecting its
ubiquitination and the successful inhibition of proteasomal
activity (Fig. 5B).
The level of p105-to-p50 processing was determined by cal-
culating the ratio of p50 to the total p105/50 complex in whole-
cell lysates of C33A cells transduced with pBabe control or
CTAR1 (Fig. 5B). The processing of p105 to p50 was enhanced
by approximately 15% in CTAR1-expressing C33A cells com-
pared to pBabe control cells. After MG132 treatment, the
percentage of processed p50 was not significantly affected in
either vector control or CTAR1-expressing cells. Treatment
with the 20S proteasomal inhibitor clasto-lactacystin -lactone
did not affect p50 processing in pBabe control cells. However,
treatment with 10 M clasto-lactacystin -lactone reduced p50
processing in CTAR1-expressing cells to approximately 40%,
which is similar to the level observed in pBabe control cells.
These findings indicate that proteasome-dependent mecha-
nisms contribute in part to LMP1 effects on p50 processing.
The effects of proteasome inhibition on the levels of nuclear
p50 are much more evident than those on p105 processing in
FIG. 3. Blocking NIK reduces LMP1-induced EGFR expression, but overexpression of NIK is not sufficient to mimic LMP1-mediated EGFR
upregulation. (A) C33A cells stably expressing CTAR1 were transfected with pCDNA3 control vector or a dominant negative NIK construct
(DNNIK), the DNNIK construct with an aly mutation (G860R; NIK-aly), or kinase-dead NIK [NIK(K-A)]. Expression levels of serine-phosphor-
ylated STAT3 and EGFR were analyzed by immunoblotting. Expression of the NIK mutants was detected by immunoblotting using antibody
against the C terminus of NIK. GAPDH was measured by immunoblotting as a loading control. The intensities of Ser-P-STAT3 and EGFR were
quantitated using Image J software and normalized to the expression level of GAPDH from three independent experiments. *, P 
 0.05. (B) C33A
and 293T cells were transfected with increasing amounts of the wild-type NIK expression construct. (C) NIKaly/aly MEF cells stably expressing
CTAR1 were transfected with increasing amounts of the wild-type NIK expression construct. CTAR1 expression was confirmed by immunoblotting
with antibody against the HA tag. The expression of NIK, EGFR, and serine-phosphorylated STAT3 was analyzed by immunoblotting. Expression
of GAPDH was measured by immunoblotting as a loading control. The images shown in panels B and C are representative of three independent
experiments.
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whole-cell lysates. This suggests that the small increased
amount of p50 is effectively transported to the nucleus.
LMP1-mediated EGFR induction requires TRAF2 and
TRAF3 but not TRAF6. Initial studies showed that the TRAF
binding motif of LMP1 was required for CTAR1-induced
EGFR expression and NF-B activation, and these effects
were decreased by dominant negative TRAF2 and TRAF3 (35,
37). To further evaluate this requirement, LMP1 and LMP1-
CTAR1 were expressed in MEF cells deficient for TRAF2,
TRAF3, or TRAF6 (Fig. 6). The expression levels of EGFR,
LMP1, and deletion mutants were determined using immuno-
blotting of whole-cell lysates (Fig. 6A). LMP1 and CTAR1
were detected using antibodies against the HA or Myc epitope
tags. Interestingly, the absence of specific TRAFs apparently
affects LMP1 modification such that the predominant LMP1
bands differ in size. EGFR was expressed at high levels in
TRAF2/ MEFs, intermediate levels were expressed in
TRAF3/ MEFs, and it was barely detected in TRAF6/
MEFs. This confirmed that the presence and absence of
TRAFs modulate expression of the EGFR. Expression of
LMP1 or CTAR1 changed these patterns of expression. In the
TRAF2-null and TRAF3-null MEFs, LMP1 or CTAR1 ex-
pression did not increase EGFR expression. In contrast, in the
TRAF6-null MEFs, LMP1 and CTAR1 clearly induced EGFR
expression (Fig. 6A). The ability of LMP1-CTAR1 to induce
EGFR in TRAF6-null MEFs but not in TRAF2- or TRAF3-
null MEFS is consistent with previously identified interactions
of CTAR1 with TRAF2 and TRAF3 but not with TRAF6.
By immunoblot analysis, the nuclear level of p50 was ana-
lyzed in TRAF2/, TRAF3/, and TRAF6/ MEFs, and
the serine phosphorylation of STAT3 was analyzed in
TRAF2/ and TRAF3/ MEF cells (Fig. 6B). Compared to
the vector control cells, CTAR1 induced nuclear expression of
p50 in TRAF3/ and TRAF6/ cells but did not affect
nuclear p50 levels in TRAF2/ MEF cells that had elevated
basal nuclear p50. In contrast, CTAR1 was able to increase
STAT3 serine phosphorylation in TRAF2/ but not
TRAF3/ MEF cells that had an elevated basal level of
STAT3 serine phosphorylation. These results indicate that
TRAF2 and TRAF3 contribute to CTAR1-mediated EGFR
induction through possible effects on p50 activation and
STAT3 serine phosphorylation, respectively.
DISCUSSION
LMP1 is a member of the TNFR family and potently acti-
vates NF-B transcriptional activity. Early studies identified
two distinct NF-B-activating domains in the carboxy termi-
nus, CTAR1 and CTAR2, and determined that CTAR2 had
greater activity in NF-B reporter assays (18, 42). However,
identification of the specific complexes using electrophoretic
mobility shifts assay (EMSA) revealed that CTAR1 activated
multiple forms of NF-B while CTAR2 primarily activated a
complex containing p65 (35). In addition, it was shown that
CTAR1 significantly enhanced processing of p100 to p52 (42).
Subsequent studies have further characterized activation of
NF-B and defined the canonical pathway, which involves the
IKK complex containing IKK, IKK, and IKK, to phosphor-
ylate and negatively regulate the inhibitor of NF-B, IB. It
is now known that CTAR2 activates the IKK (NEMO)/IKK-
dependent canonical NF-B pathway through TRAF6/IRAK1/
TAK1 (29, 46, 57). CTAR1, on the other hand, activates the
IKK (NEMO)-independent but NIK/IKK-dependent non-
canonical NF-B pathway, in addition to causing some activa-
tion of the canonical pathway (1, 9, 30). An atypical IKK-
dependent/IKK-independent NF-B activation has also been
previously described in LMP1-expressing cell culture models
(30). Our previous studies have identified an additional LMP1-
mediated activation of NF-B, in which CTAR1 of LMP1
activates two NF-B members, p50 and Bcl-3, that are induced
to bind to the EGFR promoter by LMP1 and increase EGFR
transcription (24, 52, 53). The data in this study indicate that
this novel pathway is independent of factors required for acti-
vation of the canonical or noncanonical NF-B pathways.
IKK, IKK, and IKK, all of which are important compo-
nents in the canonical NF-B pathway, were not required for
CTAR1-induced EGFR expression (Fig. 2). This result is con-
sistent with previous data indicating that CTAR2 alone was not
FIG. 4. CTAR1-mediated p50 activation is not dependent on the canonical or noncanonical NF-B pathway. Wild-type, IKK/, IKK/,
and NIKaly/aly MEF cells stably transduced with vector or CTAR1 were fractionated, and nuclear lysates were subjected to immunoblot analysis
with antibodies specifically against p65 (RelA), p50, and RelB. PARP expression was analyzed by immunoblotting as a loading control. Data are
representative of at least two independent experiments. V, vector control; C1, CTAR1.
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FIG. 5. CTAR1 mediates p50 activation through proteasome-dependent pathways. C33A cells stably transduced with vector control or CTAR1
were treated with DMSO or the proteasome inhibitor MG132 or -lactone (1 or 10 M) for 5 h and subjected to fractionation. Nuclear lysates
(A) and whole-cell lysates (B) of these cells were analyzed by immunoblotting. Antibody against p105/50 was used to detect the processing and
activation of p50. Expression of GAPDH and emerin was detected as loading controls for whole-cell lysates and nuclear lysates, respectively. The
intensities of p105/50 bands were quantitated using Image J software, and the percentage of processed p50 in whole-cell lysates was calculated as
[p50/(p50  p105)] 	 100%. The level of p50 nuclear expression was quantitated by normalizing p50 to the expression level of emerin. The data
are the averages and standard errors from three independent experiments.
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able to induce EGFR expression despite its ability to activate
strong canonical NF-B signaling (Fig. 1) (24, 35).
Although the CTAR1-mediated EGFR induction was inhib-
ited in NIKaly/aly cells, perhaps suggesting a requirement for
the noncanonical NF-B pathway, CTAR1-mediated induction
of EGFR did not require IKK, the functional kinase in the
noncanonical NF-B pathway. The decreased EGFR induc-
tion by the dominant negative NIK construct, kinase-dead
NIK(K-A), in CTAR1-expressing C33A cells suggests that
NIK does contribute to CTAR1-mediated EGFR induction
(Fig. 3A). In contrast to NIK(K-A), the truncated DNNIK
and NIK-aly did not significantly reduce CTAR1-induce
STAT3 serine phosphorylation or EGFR expression, al-
though both constructs still contain the TRAF/IKK binding
domain. These findings indicate that the N terminus of NIK
is an important contributing factor in LMP1-mediated
EGFR induction. NIK-aly has previously been shown not to
inhibit LMP1 activation of an NF-B reporter, and LMP1
also activated the NF-B reporter in the NIKaly/aly MEFs.
The lack of an effect of NIK-aly on CTAR1-induced EGFR
expression suggests that specific protein interactions and
functions mediated through the aly residue (G860R), other
than IKK interaction, are important for EGFR upregula-
tion. This result is consistent with the observation that
CTAR1 could induce EGFR expression in IKK-defective
MEFs but not in NIKaly/aly MEF cells. Despite the require-
ment for NIK in LMP1-mediated EGFR induction, overex-
pression of NIK was not sufficient to mimic CTAR1-medi-
ated STAT3 activation and EGFR upregulation in epithelial
cells, and overexpression of wild-type NIK in the presence
of CTAR1 did not induce Ser-pSTAT3 or EGFR induction
in NIK-defective cells (Fig. 3B and C). These findings sug-
gest that additional NIK-associated factors or NIK-medi-
ated effects on other kinases contribute to this pathway and
that a balance of expression level between NIK and NIK-
associated factors may be required. These findings are sim-
ilar to the requirement for TRAF3 for LMP1 signaling.
Although TRAF3 is required for LMP1-mediated signaling
pathways and transformation, overexpression of TRAF3 in
LMP1 expression cells impairs CTAR1-mediated NF-B ac-
tivation (2, 33, 35, 37). TRAF3 binds strongly to CTAR1,
and its overexpression likely alters the components in the
LMP1/TRAF complexes that activate NF-B.
It is known that both TRAF3 and TRAF2 regulate NIK, and
it is thought that TRAF3 is required to form a complex con-
taining TRAF2 and cIAP that induces NIK turnover (54). This
suggests a negative regulatory mechanism between TRAF2/
TRAF3 and NIK. However, CTAR1 failed to induce EGFR
expression in MEF cells defective for TRAF2, TRAF3, or
NIK. It is possible that LMP1-CTAR1 may mediate EGFR
upregulation through NIK by sequestering the NIK regulators
TRAF2 and TRAF3. This hypothesis would be consistent with
the ability of LMP1 to modulate formation of TRAF-contain-
ing complexes and their effects on various targets.
The other important member of the EGFR-inducing com-
plex, p50, is activated and translocated into the nucleus in
LMP1/CTAR1-expressing C33A cells (24, 42, 53). Several
mechanisms have been suggested to mediate p50 activation.
This study reveals that CTAR1-induced p50 activation is not
dependent on either the canonical or noncanonical NF-B
pathway, since this occurred in IKK-, IKK-, and NIK-defec-
tive MEF cells (Fig. 4). Interestingly, CTAR1 did not induce
significant p50 activation in WT MEF cells. This may be due to
the relatively high level of nuclear p50 in WT MEF cells and
may partially explain why LMP1 only slightly induced EGFR
expression in WT MEF cells compared to C33A or other
mutant MEF cells.
Multiple studies have suggested that p50 can be activated
through processing of its precursor, p105. This processing
could occur in ubiquitination-dependent or ubiquitination-in-
dependent fashion (3, 5, 22, 38). It was also suggested that p50
could be generated through a mechanism involved cotransla-
tional ribosome halting (27, 28). One consensus among these
FIG. 6. LMP1-mediated EGFR upregulation is TRAF2 and
TRAF3 dependent but not TRAF6 dependent. (A) TRAF2/,
TRAF3/, and TRAF6/ MEF cells were transfected (TRAF3/)
or transduced with vector control, full-length LMP1, or CTAR1, and
whole-cell lysates of these cells were subject to immunoblotting with
EGFR-specific antibodies. Expression of LMP1 or CTAR1 was con-
firmed by immunoblotting with specific antibody against full-length
LMP1 (S12), HA tag, or Myc tag (TRAF3/). Expression of GRP78
was detected as loading control. (B) TRAF2/, TRAF3/, and
TRAF6/ MEF cells expressing CTAR1 were fractionated. Nuclear
and whole-cell lysates were analyzed by immunoblotting with p50
(TRAF2/, TRAF3/, and TRAF6/ cells) and Ser-P-STAT3
(TRAF2/ and TRAF3/ cells) antibodies, respectively. Expression
of PARP and GAPDH was detected as loading controls. The results
shown are representative of at least two independent experiments.
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suggested mechanisms is that they are all proteasome depen-
dent. The data presented here indicate that CTAR1 does en-
hance processing of p50, which is consistent with previous
studies (42). Proteasome inhibition with either 26S or 20S
inhibitor reduced nuclear p50 in CTAR1-expressing cells (Fig.
5). Interestingly, both the 26S inhibitor MG132 and the 20S
inhibitor clasto-lactacystin -lactone inhibited CTAR1-in-
duced nuclear translocation of p50, with only a slight effect on
processing detected by inhibition of the 20S proteasome. This
suggests that the slightly increased levels of processed p50 are
efficiently transported to the nucleus (38). It is likely that
LMP1 regulates multiple pathways to mediate p50 activation.
This is supported by the observation that CTAR1 induced p50
activation in MEF cells defective for IKK, which has been
suggested as the kinase responsible for p105 processing (5).
Several proteins have been suggested previously to regulate
p50 translocation, including Bcl-3 and importin-3 (11, 59).
The fact that LMP1-CTAR1 induces Bcl-3 expression and nu-
clear localization makes it an attractive candidate (24, 40). It
will be of interest to determine if Bcl-3 and importins contrib-
ute to CTAR1-mediated p50 activation and induction of
EGFR.
LMP1-associated TRAFs are important for LMP1-mediated
signaling pathways, including JNK, p38, and NF-B activation
(50). Our initial studies indicated that the TRAF binding motif
of CTAR1 was required for LMP1 induction of EGFR expres-
sion (35). Expression of CTAR1 in MEF cells defective for
different TRAFs revealed that TRAF2 and TRAF3, but not
TRAF6, are required for CTAR1-mediated EGFR induction
(Fig. 6). This result is consistent with the findings that TRAF2
and TRAF3, but not TRAF6, interact with the CTAR1 TRAF
binding motif. Although TRAF6 does not interact with
CTAR1, it has been shown that TRAF6 can interact with NIK
(6). It is possible that the interaction of CTAR2 with TRAF6
modulates the TRAF6 interaction with NIK and NIK-regu-
lated activation of Ser-pSTAT3 or downstream kinases. LMP1
containing CTAR1 but deleted for CTAR2 usually has ele-
vated effects in comparison to full-length LMP1 in C33A cells
(24). The effects of the two domains on various TRAF-con-
taining complexes are likely the basis for the enhanced activity
of CTAR1 in the absence of CTAR2. It is also interesting to
note that another potential STAT3 kinase, extracellular signal-
regulated kinase (ERK), has been shown to be regulated by
NIK and that CTAR1-mediated ERK activation and transfor-
mation were also inhibited by dominant negative TRAF2 or
TRAF3, but not TRAF6 (12, 33). The interaction of LMP1
with TRAF2 and TRAF3 likely activates multiple potentially
redundant kinases that affect transcription factors that regulate
EGFR expression.
In conclusion, this study reveals that LMP1-CTAR1 induces
EGFR expression through NIK, TRAF2, and TRAF3 inde-
pendently of traditionally defined canonical and noncanonical
NF-B pathways. Two important EGFR-inducing factors,
STAT3 and p50, are regulated distinctively in the presence or
absence of various IKK and TRAF molecules. The effects of
LMP1 on the Ser-pSTAT3 potentially require NIK and
TRAF3, whereas the effects on p50 require TRAF2 but are
independent of NIK, TRAF3, and TRAF6. The data suggest
that distinct combinations of LMP1-activated effectors regu-
late the effects of LMP1 expression and its ability to induce
transformation. The further study of LMP1 and its activation
of NF-B and additional pathways will likely clarify the link
between specific signal transducing complexes and the down-
stream effectors, as well as its contribution to EBV-associated
cancer development.
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